Details for Patent: 10,111,840
✉ Email this page to a colleague
Which drugs does patent 10,111,840 protect, and when does it expire?
Patent 10,111,840 protects EPIDIOLEX and is included in one NDA.
This patent has thirty-two patent family members in nineteen countries.
Summary for Patent: 10,111,840
| Title: | Use of cannabinoids in the treatment of epilepsy |
| Abstract: | The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs). |
| Inventor(s): | Guy; Geoffrey (Cambridge, GB), Wright; Stephen (Cambridge, GB), Mead; Alice (Cambridge, GB), Devinsky; Orrin (New York, NY) |
| Assignee: | GW Pharma Limited (Vision Park, Histon, Cambridge, unknown) |
| Application Number: | 14/881,969 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,111,840 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,111,840
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME | ⤷ Sign Up | ||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,111,840
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 1418171.3 | Oct 14, 2014 |
International Family Members for US Patent 10,111,840
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015332212 | ⤷ Sign Up | |||
| Australia | 2021204353 | ⤷ Sign Up | |||
| Australia | 2023258400 | ⤷ Sign Up | |||
| Brazil | 112017007777 | ⤷ Sign Up | |||
| Canada | 2963208 | ⤷ Sign Up | |||
| Canada | 3232241 | ⤷ Sign Up | |||
| Cyprus | 1123229 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
